ArticleCancers2021

Rituximab-Containing Risk-Adapted Treatment Strategy in Nodular Lymphocyte Predominant Hodgkin Lymphoma: 7-Years Follow-Up.

Novella Pugliese et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.